LP250843-2
Vedolizumab
Active
Description
Vedolizumab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD) including the subtypes Ulcerative colitis and Crohn's disease. IBD involves inflammation of the intestinal mucosa by leukocytes that cause a disruption in its barrier function. The leukocytes involved are T-cells that express α4β7 integrins which are the target for the drug vedolizumab. Vedolizumab prevents α4β7 integrin from binding with the endothelial surface and T-cells from penetrating the intestinal mucosa. Vedolizumab has proven to be a safe and effective treatment for IBD based in clinical research. Clinical studies have shown that vedolizumab helps achieve corticosteroid-free clinical remission. PMID: 27003961 Source: Regenstrief LOINC
Basic Part Properties
- Part Name
- Vedolizumab
- Part Display Name
- Vedolizumab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2017-05-09
- Construct for LOINC Short Name
- Vedolizumab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP250843-2 - ConceptMap translate
- https:
//fhir.loinc.org/ConceptMap/$translate?system=http: //loinc.org&code=LP250843-2
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| zh-CN | Chinese (China) | 维多珠单抗 Synonyms: 维多珠; |
| es-ES | Spanish (Spain) | Vedolizumab |
| it-IT | Italian (Italy) | Vedolizumab |
| el-GR | Greek (Greece) | Βεδολιζουμάμπη Synonyms: Βεδολιζουμάμπη |
LOINC Copyright
Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://